Exelixis
EXEL
#1693
Rank
HK$92.98 B
Marketcap
HK$345.41
Share price
0.82%
Change (1 day)
24.05%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2025 : HK$1.37 Billion

According to Exelixis's latest financial reports the company's total debt is HK$1.37 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2025)

Total debt by year

Year Total debt Change
2024-12-31HK$1.48 B-0.14%
2023-12-31HK$1.48 B-0.16%
2022-12-31HK$1.48 B271.65%
2021-12-31HK$0.39 B5.06%
2020-12-31HK$0.38 B1.77%
2019-12-31HK$0.37 B220.12%
2018-12-31HK$0.11 B0.08%
2017-12-31HK$0.11 B-92.04%
2016-12-31HK$1.46 B-54.73%
2015-12-31HK$3.23 B16.99%
2014-12-31HK$2.76 B2.83%
2013-12-31HK$2.69 B3.47%
2012-12-31HK$2.60 B84.59%
2011-12-31HK$1.40 B-13.1%
2010-12-31HK$1.62 B162.79%
2009-12-31HK$0.61 B-32.12%
2008-12-31HK$0.90 B-4.02%
2007-12-31HK$0.94 B0.14%
2006-12-31HK$0.94 B-18.02%
2005-12-31HK$1.15 B0.78%
2004-12-31HK$1.14 B32.99%
2003-12-31HK$0.86 B49.34%
2002-12-31HK$0.57 B51.08%
2001-12-31HK$0.38 B227.3%
2000-12-31HK$0.11 B12.85%
1999-12-31HK$0.10 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
GlaxoSmithKline
GSK
HK$185.75 B 13,422.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
HK$198.75 B 14,368.36%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$322.08 B 23,346.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$397.33 B 28,824.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$424.94 B 30,833.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
HK$356.50 B 25,851.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$473.68 B 34,382.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Curis
CRIS
HK$15.32 M-98.88%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
HK$0.30 B-78.08%๐Ÿ‡บ๐Ÿ‡ธ USA